Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 14;13:4169–4181. doi: 10.2147/OTT.S245091

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Guo et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

LncRNA-UCA1 knockdown promotes the inhibitory effects of metformin on colon cancer and on the PI3K/AKT and ERK signaling pathways in vivo. (A and B) Metformin and UCA1 knockdown significantly inhibited the proliferation of SW480 cells in a tumor-bearing mouse model. The anticancer effect of MET was further enhanced by UCA1 downregulation. (C) Immunohistochemistry was used to explore the effects of MET or UCA1 knockdown or MET + UCA1 knockdown on the expression of PCNA and cleaved caspase 3 and the activation of the PI3K/AKT and ERK signaling pathways in the tumor tissues obtained from a tumor-bearing nude mouse model. *p-value<0.05; **p-value<0.01. One-way ANOVA is used in B.